TRIP-FAST: SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=50 | Recruiting | Sponsor: Ruijin Hospital
New P2 trial • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor
|